Tasidotin (also known as ILX-651), an orally active synthetic microtubule-targeted derivative of the marine depsipeptide dolastatin-15. It was suggested, that tasidotin has a unique mechanism of action. The drug inhibits cell proliferation by suppressing spindle microtubule dynamics through a reduction of the shortening rate, reduction of the switching frequency from growth to shortening, and reduction of the time microtubules grow. Tasidotin was studied in clinical trials phase II in patients with locally advanced or metastatic non-small cell lung carcinoma, in patients with hormone-refractory prostate cancer, and in patients with inoperable locally advanced or metastatic melanoma. However, no new results were published last 5 years. It was suggested that tasidotin is no longer being used as single or even components of multiple agents today.